2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. DNA/RNA Synthesis
  5. DNA/RNA Synthesis Agonist

DNA/RNA Synthesis Agonist

DNA/RNA Synthesis Agonists (7):

Cat. No. Product Name Effect Purity
  • HY-19620
    Branaplam
    		Agonist 99.78%
    Branaplam (LMI070; NVS-SM1) is a highly potent, selective and orally active survival motor neuron-2 (SMN2) splicing modulator with an EC50 of 20 nM for SMN. Branaplam inhibits human-ether-a-go-go-related gene (hERG) with an IC50 of 6.3 μM. Branaplam elevates full-length SMN protein and extends survival in a severe spinal muscular atrophy (SMA) mouse model.
  • HY-W009371
    D-Ribose 5-phosphate disodium
    		Agonist ≥99.0%
    D-Ribose 5-phosphate disodium is an intermediate of the oxidative branch of the pentose phosphate pathway (PPP) and an end product of the nonoxidative branch of the PPP. D-Ribose 5-phosphate disodium is used in the synthesis of nucleotides and nucleic acids.
  • HY-19620A
    Branaplam hydrochloride
    		Agonist 99.42%
    Branaplam (LMI070; NVS-SM1) hydrochloride is a highly potent, selective and orally active survival motor neuron-2 (SMN2) splicing modulator with an EC50 of 20 nM for SMN. Branaplam hydrochloride inhibits human-ether-a-go-go-related gene (hERG) with an IC50 of 6.3 μM. Branaplam hydrochloride elevates full-length SMN protein and extends survival in a severe spinal muscular atrophy (SMA) mouse model.
  • HY-111520
    NVS-SM2
    		Agonist 99.15%
    NVS-SM2 is a potent, orally active and brain-penetrant SMN2 splicing enhancer with an EC50 of 2 nM for SMN. NVS-SM2 enhances U1-pre-mRNA association. NVS-SM2 promotes exon 7 inclusion and restores normal survival motor neuron (SMN) protein expression. NVS-SM2 can be used for spinal muscular atrophy (SMA) research.
  • HY-W002339
    3-Hydroxy-2-methylpyridine
    		Agonist ≥98.0%
    3-Hydroxy-2-methylpyridine, isolated from alkaline extracts of cocoa, is used in the synthesis of pyrimidine.
  • HY-161470
    WS-384
    		Agonist
    WS-384 is a dual LSD1 and DCN1-UBC12 protein-protein interaction inhibitor with oral activity, with IC50 values of 338.79 nM and 14.81 nM, respectively. WS-384 possesses anticancer activity and can cause cell cycle arrest, DNA damage, and induce apoptosis. WS-384 can be used in the research of non-small cell lung cancer (NSCLC).
  • HY-117846
    MLAF50
    		Agonist
    MLAF50 is apotent REV1 UBM2-Ubiquitin interaction inhibitor. MLAF50 inhibits chromatin co-localization of REV1 with PCNA following DNA-damage induction.